B
Burosumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Burosumab
General information
Subsidy Information and Financing Scheme
[MAF] Burosumab (Crysvita) Solution For Injection 10 mg/mL, 20 mg/mL, and 30 mg/mL
Additional clinical criteria applies
Treatment of X-linked hypophosphataemia (XLH) in adults and children 1 year of age and older.
Drug Guidance for Subsidy
04/06/2024 Burosumab for treating X-linked hypophosphataemia
The Ministry of Health’s Drug Advisory Committee has recommended:
Burosumab 10 mg/mL, 20 mg/mL and 30 mg/mL solution for injection for treating X-linked hypophosphataemia (XLH) in adults and children 1 year of age and older, in line with the following criteria:
Patient must have a documented confirmation of PHEX pathogenic variant; or
Patient must have a confirmed diagnosis of XLH demonstrated by the presence of all of the following:
a serum phosphate concentration below the age adjusted lower limit of normal;
current or historical (for those with growth plate fusion) radiographic X-ray evidence of rickets;
renal phosphate wasting demonstrated by a ratio of tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) according to age specific normal ranges using the second morning urine void and paired serum sample measuring phosphate and creatinine; and
Patient must be treated by, or in consultation with, a specialist physician experienced in the diagnosis and management of XLH.
Funding status
[R] Burosumab 10 mg/mL, 20 mg/mL and 30 mg/mL solution for injection are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Crysvita Solution For Injection 10 mg/mL |
|
Crysvita Solution For Injection 20 mg/mL |
|
Crysvita Solution For Injection 30 mg/mL |
|